Carolina Oncology Specialists, PA ( Site 9002) — Charlotte, North Carolina

Carolina Oncology Specialists, PA ( Site 9002) is a clinical research site located in Charlotte, North Carolina, United States 28207.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

Carolina Oncology Specialists, PA ( Site 9002) has participated in 2 clinical trials with 2 currently active.

Therapeutic areas: Renal Cell Carcinoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.

Sponsors: Merck Sharp & Dohme LLC.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Charlotte

Browse all research sites in North Carolina · View every site in Charlotte

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Carolina Oncology Specialists, PA ( Site 9002)?

Carolina Oncology Specialists, PA ( Site 9002) has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Carolina Oncology Specialists, PA ( Site 9002) conducted?

Carolina Oncology Specialists, PA ( Site 9002) has 2 clinical trials on record, with 2 currently active. Their work covers Renal Cell Carcinoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.

Is Carolina Oncology Specialists, PA ( Site 9002) accredited by Crixeo Clinical Trials?

Carolina Oncology Specialists, PA ( Site 9002) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Carolina Oncology Specialists, PA ( Site 9002)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.